← Back

Hangzhou Minsheng Healthcare Co Ltd

Hangzhou Minsheng Healthcare Co., Ltd. researches, develops, produces, and sells vitamins and mineral supplements, OTC drugs, and healthy foods in China and internationally. Its products include fish and algae oil gel candy, collagen peptide vitamin D calcium chewable tablets, blueberry lutein ester candy tablets, probiotic solid beverage, multivitamin and mineral tablets, glucosamine chondroitin colostrum protein chewables, vitamin soft capsules and chewables, iron folic acid, melatonin, coenzyme soft capsules, and calcium magnesium vitamin D tablets. The company offers its products under the 21 SUPER-VITA brand. Founded in 1926, it is based in Hangzhou, China.

Country
Price · split & dividend adjusted
News & notes moving 301507.CS
301507.CS4

Minsheng Health Releases 2026 Interim Report with Net Profit of 83.3943 Million Yuan

Minsheng Health released its 2026 interim report on August 28, 2026. During the reporting period, the company achieved total operating revenue of 535 million yuan and net profit attributable to the parent company of 83.3943 million yuan. Net cash inflow from operating activities was 137 million yuan, a decrease of 5.2026 million yuan compared with the same period last year, down 3.67 percent year on year. The company's asset-liability ratio was 17.68 percent, up 2.13 percentage points from the previous quarter and up 3.00 percentage points from the same period last year. Gross margin was 55.17 percent, down 2.61 percentage points from the previous quarter. Return on equity was 5.17 percent, down 0.05 percentage points from the same period last year. Diluted earnings per share were 0.23 yuan. Total asset turnover was 0.26 times, and inventory turnover was 2.79 times. The number of shareholders was 17,600, and the top ten shareholders held 255 million shares, accounting for 71.59 percent of total share capital.
Jiemian·22dRead more →
301507.CS

Minsheng Health Completes 2.32 Million Share Buyback at a Cost of 34.15 Million Yuan

Minsheng Health announced that as of July 31, 2026, it had repurchased 2.32 million shares, representing 0.65% of total share capital, at a price range of 11.77 yuan to 15.67 yuan per share, with a total buyback amount of 34.15 million yuan. In the first quarter of 2026, the company achieved revenue of 317 million yuan and net profit attributable to the parent of 62.78 million yuan.
财中社·45dRead more →